[1]
D. H. S. Pelliciari, C. R. A. Reis, and C. A. Bordini, “Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study”, Headache Med, vol. 15, no. 3, pp. 170–174, Sep. 2024.